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Prostaglandin E2 Receptor Regulates Metastasis and 
Stem-Cell Like Properties in Triple-Negative Breast 
Cancer Through SCL19A3
Vivian Shin1, Isabella Cheuk1, Man-Ting Siu1, John Ho1, Jia-Wei Chen1,  
Hong-Chuan Jin2, Ava Kwong1* 
1Department of Surgery, The University of Hong Kong, Hong Kong
2Department of Laboratory of Cancer Biology, Biomedical Research Center, SRRS Hospital, 
China 
Background/Purpose: Majority of BRCA1 mutation-associated tumors share pheno-
typic similarity to triple-negative breast cancer (TNBC), understanding the biology of 
TNBC may improve management of these patients. TNBC is associated with increased 
risk of metastatic disease and poor prognosis. Prostaglandin E (EP) receptors have been 
associated with tumor metastasis, however, the contribution on cancer stem cell com-
partment remains unstudied. 
Methods: EP2 was predominantly expressed in human primary tumor tissues. A stable 
EP2-expression cell line was used to study tumorigenesis and distant metastasis in meta-
static breast cancer mice model. Larger tumors and more distant metastasis were seen in 
MD-231-EP2 bearing mice when compared with control. Characterization of EP2 re-
ceptor on cell proliferation, flow cytometry and invasion were performed in transfected 
cells. Profiles of drug transporters and epithelial–mesenchymal transition (EMT) genes 
were compared. Tumorsphere assay was used to examine the stem-cell like properties. 
Results: EP2 siRNA or antagonist (AH6809) retarded cell proliferation and invasion. 
Upregulation of SLC19A3 and downregulation of ZEB1 and Twist were observed by 
blocking EP2. There was an inverse correlation between EP2 and SLC19A3 in primary 
tumors. Overexpression of SLC19A3 retarded breast cancer growth and EMT pheno-
type. Enhanced expression of Aldehyde dehydrogenase (ALDH) (cancer stem cell 
marker) was seen in xenograft tumors. Twist and ALDH expression were increased in 
tumorspheres and the ALDH activity was reduced by blocking EP2. Twist expression 
was higher in breast cancer patients and was associated with ALDH expression. 
Conclusion: Taken together, EP2/SLC19A3 signaling axis regulates metastasis and 
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stem-like cell properties in TNBC. These findings suggest that targeting EP2 receptor of-
fers a therapeutic strategy for TNBC. 
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